Randomized placebo-controlled trials of omega-3 polyunsaturated fatty acids in psychiatric disorders: A review of the current literature

Current Drug Discovery Technologies

Volumn 10, Issue 3, 2013, Pages 245-253

  Politi, Pierluigi ^a   Rocchetti, Matteo ^a   Emanuele, Enzo ^a   Rondanelli, Mariangela ^a   Barale, Francesco ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Docosahexaenoic acid; Eicosapentaenoic acid; Omega 3; Psychiatric disorders; Trials

Indexed keywords

DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID;

ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; AUTISM; HUMAN; MENTAL DISEASE; MOOD DISORDER; PERSONALITY DISORDER; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SHORT TERM MEMORY; SUPPLEMENTATION;

FATTY ACIDS, OMEGA-3; HUMANS; MENTAL DISORDERS;

EID: 84882301131     PISSN: 15701638     EISSN: 18756220     Source Type: Journal    
DOI: 10.2174/1570163811310030007     Document Type: Review

References (84)

1. Burr GO, Burr MM. A new deficiency disease produced by the rigid exclusion of fat from the diet. J Biol Chem 1929; 82: 345-67.
2. Burr GO, Burr MM. On the nature and role of the essential fatty acids in nutrition. J Biol Chem 1930; 86: 587-621.
3. Sinclair HM. Essential fatty acids: an historical perspective. Biochem Soc Trans 1990; 18: 756-61.
4. Pawlosky RJ, Hibbeln JR, Novotny JA, Salem N Jr. Physiological compartmental analysis of alpha-linolenic acid metabolism in adult humans. J Lipid Res 2001; 42: 1257-65.
5. Simopolous AP, Kifer RR, Martin RE. Health effects of polyunsaturated fatty acids in seafoods. New York Academic 1986.
6. Brenna JT. Efficiency of conversion of alpha-linolenic acid to long chain n3 fatty acids in man. Curr Opin Clin Nutr Metab Care 2002; 5: 127-32.
7. Wallis JG, Watts JL, Browse J. Polyunsaturated fatty acid synthesis: what will they think of next? Trends Biochem Sci 2002; 27: 467.
8. Gerster H. Can adults adequately convert alpha-linolenic acid (18:3n-3) to eicosapentaenoic acid (20:5n-3) and docosahexaenoic acid (22:6n-3)? Int J Vitam Nutr Res 1998; 68: 159-73.
9. Schaeffer L, Gohlke H, Müller M, et al. Common genetic variants of the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids. Hum Mol Genet 2006; 15: 1745-56.
10. Lattka E, Illig T, Koletzko B, Heinrich J. Genetic variants of the FADS1 FADS2 gene cluster as related to essential fatty acid metabolism. Curr Opin Lipidol 2010; 21: 64-9.
11. Burdge GC, Wootton SA. Conversion of alpha-linolenic acid to eicosapentaenoic, docosapentaenoic and docosahexaenoic acids in young women. Br J Nutr 2002; 88: 411-20.
12. Burdge GC, Jones AE, Wootton SA. Eicosapentaenoic and docosapentaenoic acids are the principal products of alphalinolenic acid metabolism in young men. Br J Nutr 2002; 88: 355-63.
13. Galland L. Impaired essential fatty acid metabolism in latent tetany. Magnesium 1995; 4: 333-8.
14. Arnold LE, DiSilvestro RA. Zinc in attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2005; 15: 619-27.
15. Schuchardt JP, Huss M, Stauss-Grabo M, Hahn A. Significance of long-chain polyunsaturated fatty acids (PUFAs) for the development and behaviour of children. Eur J Pediatr 2010; 169: 149-64.
16. Wietrzych-Schindler M, Szyszka-Niagolov M, Ohta K, et al. Retinoid X Receptor Gamma Is Implicated in Docosahexaenoic Acid Modulation of Despair Behaviors and Working Memory in Mice. Biol Psychiatry 2011; 69: 788-94.
17. Krzyzosiak A, Szyszka-Niagolov M, Wietrzych M, Gobaille S, Muramatsu S, Krezel W. Retinoid x receptor gamma control of affective behaviors involves dopaminergic signaling in mice. Neuron 2010; 66: 908-20.
18. Nakamura MT, Cheon Y, Li Y, Nara TY. Mechanisms of regulation of gene expression by fatty acids. Lipids 2004; 39: 1077-83.
19. Sampath H, Ntambi JM. Polyunsaturated fatty acid regulation of genes of lipid metabolism. Annu Rev Nutr 2005; 25: 317-40.
20. Jump DB, Botolin D, Wang Y, Xu J, Christian B, Demeure O. Fatty acid regulation of hepatic gene transcription. J Nutr 2005; 135: 2503-6.
21. Kitajka K, Sinclair AJ, Weisinger RS. Effects of dietary omega-3 polyunsaturated fatty acids on brain gene expression. Proc Natl Acad Sci USA 2004; 101: 10931-6.
22. Jouvent R, Abensour P, Bonnet AM, Widlocher D, Agid Y, Lhermitte F. Antiparkinsonian and antidepressant effects of high doses of bromocriptine. An independent comparison. J Affect Disord 1983; 5: 141-5.
23. Mattes JA. Pergolide to augment the effectiveness of antidepressants: clinical experience and a small double-blind study. Ann Clin Psychiatry 1997; 9: 87-8.
24. Bourre JM, Francois M, Youyou A, et al. The effects of dietary alpha-linolenic acid on the composition of nerve membranes, enzymatic activity, amplitude of electrophysiological parameters, resistance to poisons and performance of learning tasks in rats. J Nutr 1989; 119: 1880-92.
25. Ahmed FA, Hegazy K, Chaudhary P, Sharma SC. Neuroprotective effect of alpha(2) agonist (brimonidine) on adult rat retinal ganglion cells after increased intraocular pressure. Brain Res 2001; 913: 133-9.
26. Martin RE. Docosahexaenoic acid decreases phospholipase A2 activity in the neurites/nerve growth cones of PC12 cells. J Neurosci Res 1998; 54: 805-13.
27. Wu A, Ying Z, Gomez-Pinilla F. Docosahexaenoic acid dietary supplementation enhances the effects of exercise on synaptic plasticity and cognition. Neuroscience 2008; 155: 751-9.
28. Lafourcade M, Larrieu T, Mato S, et al. Nutritional omega-3 deficiency abolishes endocannabinoid-mediated neuronal functions. Nat Neurosci 2011; 14: 345-50.
29. Koletzko B, Lien E, Agostoni C, et al. The roles of longchain polyunsaturated fatty acids in pregnancy, lactation and infancy: review of current knowledge and consensus recommendations. J Perinat Med 2008; 36: 5-14.
30. Chalon S, Delion-Vancassel S, Belzung C. Dietary fish oil affects monoaminergic neurotransmission and behavior in rats. J Nutr 1998; 128: 2512-9.
31. Zimmer L, Vancassel S, Cantagrel S, et al. The dopamine mesocorticolimbic pathway is affected by deficiency in n3 polyunsaturated fatty acids. Am J Clin Nutr 2002; 75: 662-7.
32. Kodas E, Galineau L, Bodard S, et al. Serotoninergic neurotransmission is affected by n3 polyunsaturated fatty acids in the rat. J Neurochem 2004; 89: 695-702.
33. Song C, Manku MS, Horrobin DF. Long-chain polyunsaturated fatty acids modulate interleukin-1beta-induced changes in behavior, monoaminergic neurotransmitters, and brain inflammation in rats. J Nutr 2008; 138: 954-63.
34. Ahmad SO, Park JH, Radel JD, Levant B. Reduced numbers of dopamine neurons in the substantia nigra pars compacta and central tegmental area of rats fed an n3 polyunsaturated fatty aciddeficient diet: a stereological study. Neurosci Lett 2008; 438: 303-7.
35. Feller SE, Gawrisch K, MacKerell AD Jr. Polyunsaturated fatty acids in lipid bilayers: intrinsic and environmental contributions to their unique physical properties. J Am Chem Soc 2002; 124: 318-26.
36. Chalon S. Omega-3 fatty acids and monoamine neurotransmission. Prostaglandins Leukot Essent Fatty Acids 2006; 75: 259-69.
37. Vreugdenhil M, Bruehl C, Voskuyl RA, Kang JX, Leaf A, Wadman WJ. Polyunsaturated fatty acids modulate sodium and calcium currents in CA1 neurons. Proc Natl Acad Sci USA 1996; 93: 12559-63.
38. Layé S. Polyunsaturated fatty acids, neuroinflammation and well being. Prostaglandins Leukot Essent Fatty Acids 2010; 82: 295-303.
39. Kim HY, Akbar M, Lau A. Effects of docosapentaenoic acid on neuronal apoptosis. Lipids 2003; 38: 453-7.
40. Hussain ST, Roots BI. Effect of essential fatty acid deficiency & immunopathological stresses on blood brain barrier (B-BB) in Lewis rats: a biochemical study. Biochem Soc Trans 1994; 22: 338S.
41. Simopoulos AP. Omega-3 fatty acids in health and disease and in growth and development. Am J Clin Nutr 1991; 54: 438-63.
42. Pauling L. Orthomolecular psychiatry. Varying the concentrations of substances normally present in the human body may control mental disease. Science 1968; 160: 265-71.
43. Reading CM. Orthomolecular psychiatry. Med J Aust 1979; 2: 40.
44. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association 1994.
45. Fux M, Benjamin J, Nemets B. A placebo-controlled cross-over trial of adjunctive EPA in OCD. J Psychiatr Res 2004; 38: 323-5.
46. Buydens-Branchey L, Branchey M. n-3 polyunsaturated fatty acids decrease anxiety feelings in a population of substance abusers. J Clin Psychopharmacol 2006; 26: 661-5.
47. Buydens-Branchey L, Branchey M, Hibbeln JR. Associations between increases in plasma n-3 polyunsaturated fatty acids following supplementation and decreases in anger and anxiety in substance abusers. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 568-75.
48. Zecavati N, Spence SJ. Neurometabolic disorders and dysfunction in autism spectrum disorders. Curr Neurol Neurosci Rep 2009; 9: 129-36.
49. Amminger GP, Berger GE, Schäfer MR, Klier C, Friedrich MH, Feucht M. Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study. Biol Psychiatry 2007; 61: 551-3.
50. Politi P, Cena H, Comelli M, et al. Behavioral effects of omega-3 fatty acid supplementation in young adults with severe autism: an open label study. Arch Med Res 2008; 39: 682-5.
51. Kooij SJ, Bejerot S, Blackwell A, et al. European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. BMC Psychiatry 2010; 10: 67.
52. Faraone SV, Sergeant J, Gillberg C. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry 2003; 2: 104-13.
53. Milberger S, Biederman J, Faraone SV, Guite J, Tsuang MT. Pregnancy, delivery and infancy complications and attention deficit hyperactivity disorder: issues of gene-environment interaction. Biol Psychiatry 1997; 41: 65-75.
54. Richardson AJ, Puri BK. The potential role of fatty acids in attention-deficit/hyperactivity disorder. Prostaglandins Leukot Essent Fatty Acids 2000; 63: 79-87.
55. Burgess JR, Stevens L, Zhang W, Peck L. Long-chain polyunsaturated fatty acids in children with attention-deficit hyperactivity disorder. Am J Clin Nutr 2000; 71: 327-30.
56. Joshi K, Lad S, Kale M, et al. Supplementation with flax oil and vitamin C improves the outcome of Attention Deficit Hyperactivity Disorder (ADHD). Prostaglandins Leukot Essent Fatty Acids 2006, 74: 17-21.
57. Voigt RG, Llorente AM, Jensen CL, Fraley JK, Berretta MC, Heird WC. A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attentiondeficit/hyperactivity disorder. J Pediatr 2001; 139: 189-96.
58. Hirayama S, Hamazaki T, Terasawa K. Effect of docosahexaenoic acid-containing food administration on symptoms of attentiondeficit/ hyperactivity disorder -A placebo-controlled double-blind study. Eur J Clin Nutr 2004; 58: 467-73.
59. Stevens L, Zhang W, Peck L, et al. EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. Lipids 2003, 38: 1007-21.
60. Richardson AJ, Montgomery P. The Oxford-Durham study: a randomized, controlled trial of dietary supplementation with fatty acids in children with developmental coordination disorder. Pediatrics 2005, 115: 1360-6.
61. Sinn N, Bryan J. Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with child ADHD. J Dev Behav Pediatr 2007; 28: 82-91.
62. Sinn N, Bryan J, Wilson C. Cognitive effects of polyunsaturated fatty acids in children with attention deficit hyperactivity disorder symptoms: a randomised controlled trial. Prostaglandins Leukot Essent Fatty Acids 2008; 78: 311-26.
63. Vaisman N, Kaysar N, Zaruk-Adasha Y, et al. Correlation between changes in blood fatty acid composition and visual sustained attention performance in children with inattention: effect of dietary n-3 fatty acids containing phospholipids. Am J Clin Nutr 2008; 87: 1170-80
64. Johnson M, Ostlund S, Fransson G, Kadesjö B, Gillberg C. Omega-3/omega-6 fatty acids for attention deficit hyperactivity disorder: a randomized placebo-controlled trial in children and adolescents. J Atten Disord 2009; 12: 394-401.
65. Appleton KM, Rogers PJ, Ness AR. Updated systematic review and meta-analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressed mood. Am J Clin Nutr 2010; 91: 757-70.
66. Montgomery P, Richardson AJ. Omega-3 fatty acids for bipolar disorder. Cochrane Database Syst Rev 2008; (2): CD005169.
67. Zanarini MC, Frankenburg FR. Omega-3 Fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. Am J Psychiatry 2003; 160: 167-9.
68. Horrobin DF. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr Res 1998; 30: 193-208.
69. Teale MC. Omega-3 fatty acid research. Nova Science Publishers: New York 2006.
70. Peet M, Brind J, Ramchand CN, Shah S, Vankar GK. Two doubleblind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr Res 2001; 49: 243-51.
71. Peet M, Horrobin DF, E-E Multicentre Study Group. A doseranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J Psychiatr Res 2002; 36: 7-18.
72. Horrobin DF, Jenkins K, Bennett CN, Christie WW. Eicosapentaenoic acid and arachidonic acid: collaboration and not antagonism is the key to biological understanding. Prostaglandins Leukot Essent Fatty Acids 2002; 66: 83-90.
73. Fenton WS, Dickerson F, Boronow J, Hibbeln JR, Knable M. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry 2001; 158: 2071-74.
74. Emsley R, Myburgh C, Oosthuizen P, van Rensburg SJ. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am J Psychiatry 2002; 159: 1596-8.
75. van Rensburg SJ, Smuts CM, Hon D, et al. Changes in erythrocyte membrane fatty acids during a clinical trial of eicosapentaenoic acid (EPA) supplementation in schizophrenia. Metab Brain Dis 2009; 24: 659-72.
76. Hibbeln JR, Makino KK, Martin CE, Dickerson F, Boronow J, Fenton WS. Smoking, gender, and dietary influences on erythrocyte essential fatty acid composition among patients with schizophrenia or schizoaffective disorder. Biol Psychiatry 2003; 53: 431-41.
77. Emsley R, Niehaus DJ, Koen L, et al. The effects of eicosapentaenoic acid in tardive dyskinesia: a randomized, placebocontrolled trial. Schizophr Res 2006; 84: 112-20.
78. Amminger GP, Schäfer MR, Papageorgiou K, et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2010; 67: 146-54.
79. Emsley R, Niehaus DJ, Oosthuizen PP, et al. Safety of the omega-3 fatty acid, eicosapentaenoic acid (EPA) in psychiatric patients: results from a randomized, placebo-controlled trial. Psychiatry Res 2008; 161: 284-91.
80. Yung AR, Phillips LJ, McGorry PD, et al. Prediction of psychosis. A step towards indicated prevention of schizophrenia. Br J Psychiatry Suppl 1998; 172: 14-20.
81. McGorry PD, Yung AR, Phillips LJ, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002; 59: 921-28.
82. Preti A, Cella M. Randomized-controlled trials in people at ultra high risk of psychosis: a review of treatment effectiveness. Schizophr Res 2010; 123: 30-6.
83. Bourre JM, Durand G, Pascal G, Youyou A. Brain cell and tissue recovery in rats made deficient in n3 fatty acids by alteration of dietary fat. J Nutr 1989; 119: 15-22.
84. McGahon BM, Martin DS, Horrobin DF, Lynch MA. Age-related changes in synaptic function: analysis of the effect of dietary supplementation with omega-3 fatty acids. Neuroscience 1999; 94: 305-14.